Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.53 |
| ▸ | ACP1 | P24666 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 6/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | GALK1 | P51570 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.52 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5460170 | 1.00 | PTPN1 (0.53) | PTPN1ACP1MEN1KMT2APOLB | |
| SCHEMBL5461395 | 0.91 | PTPN1 (0.54) | PTPN1ACP1MEN1KMT2APOLB | |
| SCHEMBL5461397 | 0.91 | PTPN1 (0.54) | PTPN1ACP1MEN1KMT2APOLB | |
| SCHEMBL5476536 | 0.88 | PTPN1 (0.53) | PTPN1ACP1MEN1KMT2APOLB | |
| SCHEMBL5476532 | 0.88 | PTPN1 (0.53) | PTPN1ACP1MEN1KMT2APOLB | |
| SCHEMBL5461860 | 0.83 | PTPN1 (0.51) | PTPN1ACP1MEN1KMT2APOLB | |
| SCHEMBL5461857 | 0.83 | PTPN1 (0.51) | PTPN1ACP1MEN1KMT2APOLB | |
| SCHEMBL5460189 | 0.83 | MEN1 (0.62) | MEN1KMT2APOLBUSP2ALDH1A1 | |
| SCHEMBL5460188 | 0.83 | MEN1 (0.62) | MEN1KMT2APOLBUSP2ALDH1A1 | |
| SCHEMBL5461602 | 0.83 | MEN1 (0.60) | PTPN1ACP1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12383579-B2 | Materials and methods of using an inhibitor of plasminogen activation to treat anastomotic leak | THE UNIVERSITY OF CHICAGO (US) | 2025-08-12 | — | — | US | disclosed |
| US-12274691-B2 | Envenomation therapies and related pharmaceutical compositions, systems and kits | OPHIREX, INC (US) | 2025-04-15 | — | — | US | disclosed |
| US-20240382452-A1 | COMPOSITIONS AND DOSAGE FORMS FOR TOPICAL AND TRANSDERMAL DELIVERY OF ACTIVES AND METHODS OF USE | OPHIREX INC (US) | 2024-11-21 | — | — | US | disclosed |
| US-20230305023-A1 | METHODS OF TREATMENT AND DIAGNOSTIC OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH INTENSE STRESS | INST NAT SANTE RECH MED (FR) | 2023-09-28 | — | — | US | disclosed |
| US-20230305023-A1 | METHODS OF TREATMENT AND DIAGNOSTIC OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH INTENSE STRESS | INST NAT SANTE RECH MED (FR) | 2023-09-28 | — | — | US | disclosed |
| WO-2023086343-A1 | COMPOSITIONS AND DOSAGE FORMS FOR TOPICAL AND TRANSDERMAL DELIVERY OF ACTIVES AND METHODS OF USE | OPHIREX, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| EP-4171527-A1 | METHODS OF TREATMENT AND DIAGNOSTIC OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH INTENSE STRESS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2023-05-03 | — | — | EP | disclosed |
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1666469-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | Institute of Medicinal Molecular Design, Inc. (JP) | 2006-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12274691-B2 | Envenomation therapies and related pharmaceutical compositions, systems and kits | PLA2R1, PLA2G12A, ACHE | PTPN1 4709/4885ACP1 4475/4885MEN1 2353/4885 |
| US-12383579-B2 | Materials and methods of using an inhibitor of plasminogen activation to treat anastomotic leak | PLAT, PLG, SERPINB10 | PTPN1 2253/4885ACP1 12/4885MEN1 4640/4885 |
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | SERPINE1, SERPINC1, SERPINB1 | PTPN1 3264/4885ACP1 254/4885MEN1 2892/4885 |
| US-20230305023-A1 | METHODS OF TREATMENT AND DIAGNOSTIC OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH INTENSE STRESS | SERPINE1, SERPINA6, F2RL1 | PTPN1 4119/4885ACP1 1066/4885MEN1 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.